CXCR4 and neoplasm: In contrast, we did not observe tumor growth inhibition upon CXCR4 inhibitor (AMD3100) treatment in immuno-deficient patient-derived xenograft (PDX) models of ovarian cancer (Supplementary Fig. 7), suggesting that immunosuppressive functions mediated by both CXCL12α and CXCL12β isoforms on T lymphocytes could be crucial for ovarian tumor growth.